Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two ...
Combination therapy seeks to improve intraocular pressure lowering by pairing a novel EVP-targeting agent with prostaglandin analogue standard of care DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., ...
QLS-111 relaxes vasculature tissues distal to the trabecular meshwork, including collector channels, intrascleral vessels, and episcleral vessels. The presentations will underscore QLS-111’s unique ...
Qlaris Bio has reported positive topline outcomes from two randomised Phase II US trials, Osprey and Apteryx, of QLS 111 in individuals with primary open-angle glaucoma (POAG) and ocular hypertension ...
Touting its novel approach for treating glaucoma, Qlaris Bio Inc. reported promising top-line data from two phase II studies testing QLS-111 in patients with primary open-angle glaucoma and ocular ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Qlaris Bio raised $24 million during ...
QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass., February 05, 2025--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage ...
QLS-111’s novel intraocular pressure-lowering mechanism targeting EVP to be highlighted in an oral presentation and two poster presentations DEDHAM, Mass., June 23, 2025--(BUSINESS WIRE)--Qlaris Bio, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback